(Health-NewsWire.Net, April 28, 2015 ) This report provides comprehensive information on the therapeutic development for Left Ventricular Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction and special features on late-stage and discontinued projects.
Complete report on H1 2015 pipeline review of “Left Ventricular Dysfunction” addiction with 21 market data tables and 14 figures, spread across 57 pages is available at http://www.rnrmarketresearch.com/left-ventricular-dysfunction-pipeline-review-h1-2015-market-report.html . (This is a premium report price at US$2000 for a single user PDF license)
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
• The report reviews key players involved in the therapeutics development for Left Ventricular Dysfunction and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Left Ventricular Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=310154 .
Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Reasons to Buy:
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Left Ventricular Dysfunction
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Left Ventricular Dysfunction pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
More reports on Cardiovascular therapeutics :
Pulmonary Arterial Hypertension – Pipeline Review, H1 2015
Global Markets Direct’s, Pulmonary Arterial Hypertension – Pipeline Review, H1 2015′, provides an overview of the Pulmonary Arterial Hypertension’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.
Complete report is available at http://www.rnrmarketresearch.com/pulmonary-arterial-hypertension-pipeline-review-h1-2015-market-report.html .
RnR Market Research
+ 1 888 391 5441